ReviewJournal of hematology & oncology2022
Altered pathways and targeted therapy in double hit lymphoma.
Review in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 28 citations in OpenAlex.
- Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma.Blood advances · 2026Trial
- Review
- Biomaterials Based on Bacteria for Cancer Clinical Therapy.Biomaterials research · 2026Review
- The global landscape of non-Hodgkin lymphoma incidence and mortality in 2022 and projections to 2045.Archives of medical science : AMS · 2026Article
- Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.Journal of translational medicine · 2025Article
- Microwave-Enhanced Synthesis of 2-Styrylquinoline-4-Carboxamides With Promising Anti-Lymphoma Activity.Archiv der Pharmazie · 2025Article
- Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025Review
- A 6-tsRNA signature for early detection, treatment response monitoring, and prognosis prediction in diffuse large B cell lymphoma.Blood cancer journal · 2025Article
- Clinico-pathologic Profile of Filipino Patients Diagnosed with Diffuse Large B-Cell Lymphoma, Germinal Center or Non-germinal Center Subtype Treated in a Public Tertiary Hospital from 2016 to 2021.Acta medica Philippina · 2025Article
- Article
- Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL.Blood advances · 2024Article
- Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.Journal of cancer research and clinical oncology · 2024Article
- Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.Journal of hematopathology · 2024Article
- Article
- A case of successful chemotherapy in an elderly double-hit lymphoma patient with a giant tumor, severe renal impairment, and unfavorable performance status.Geriatrics & gerontology international · 2024Article
- MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.Blood advances · 2024Article
- Primary cardiac large B cell lymphoma.BMJ case reports · 2023Article
- Image-Based Deep Learning Detection of High-Grade B-Cell Lymphomas Directly from Hematoxylin and Eosin Images.Cancers · 2023Article
- Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC-driven lymphoma.EMBO molecular medicine · 2023Article
- Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade B-cell lymphoma with translocations involving MYC and BCL2 or BCL6, usually referred to as double hit lymphoma (DHL), is an aggressive hematological malignance with distinct genetic features and poor clinical prognosis. Current standard chemoimmunotherapy fails to confer satisfying outcomes and few targeted therapeutics are available for the treatment against DHL. Recently, the delineating of the genetic landscape in tumors has provided insight into both biology and targeted therapies. Therefore, it is essential to understand the altered signaling pathways of DHL to develop treatment strategies with better clinical benefits. Herein, we summarized the genetic alterations in the two DHL subtypes (DHL-BCL2 and DHL-BCL6). We further elucidate their implications on cellular processes, including anti-apoptosis, epigenetic regulations, B-cell receptor signaling, and immune escape. Ongoing and potential therapeutic strategies and targeted drugs steered by these alterations were reviewed accordingly. Based on these findings, we also discuss the therapeutic vulnerabilities that coincide with these genetic changes. We believe that the understanding of the DHL studies will provide insight into this disease and capacitate the finding of more effective treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.